Foghorn Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FHTX research report →
Range $2 – $5
Price Chart
About the company
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system.
- CEO
- Adrian H. Gottschalk
- IPO
- 2020
- Employees
- 106
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on FHTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $113.14M
- P/E
- -1.95
- PEG
- -0.11
- P/S
- 3.08
- P/B
- -1.68
- EV/EBITDA
- -1.41
- Div Yield
- 0.00%
- Gross Margin
- 42.73%
- Op Margin
- -186.38%
- Net Margin
- -175.78%
- ROE
- 72.64%
- ROIC
- -44.00%
Latest fiscal year · YoY change
- Revenue
- $30.91M+36.8%
- Gross Profit
- $27.58M+22.0%
- Op Income
- $-82,107,000
- Net Income
- $-74,283,000+14.2%
- EPS
- $-1.18+25.3%
- OCF Growth
- +14.2%
- FCF Growth
- +15.0%
- 52W High
- $7.61
- 52W Low
- $1.79
- 50D MA
- $5.05
- 200D MA
- $5.03
- Beta
- 2.86
- RSI (14)
- 12
- Avg Volume
- 625.63K
No earnings-call transcripts are available for FHTX yet.
- Free Float
- 46.7%
- Shares Outstanding
- 58.71M
- Float Shares
- 27.41M
of shares held by institutions
104 13F filers
Buy/sell ratio 5.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Flagship Pioneering Inc. | 12.67M | 0 |
| Bvf Inc/Il | 5.84M | 0 |
| Fmr LLC | 5.71M | ▼ 341.24K |
| Deerfield Management Company, L.P. (Series C) | 4.39M | 0 |
| Blackrock, Inc. | 2.63M | ▲ 261.97K |
| Raymond James Financial Inc | 2.49M | ▼ 112.40K |
| Vanguard Group Inc | 1.93M | ▲ 29.54K |
| Euclidean Capital LLC | 1.57M | 0 |
| Vanguard Capital Management LLC | 1.49M | ▼ 478 |
| Geode Capital Management, LLC | 910.87K | ▲ 62.69K |
| Siren, L.L.C. | 720.72K | 0 |
| State Street Corp | 697.47K | ▲ 17.68K |
Held by 104 ETFs
Biggest fund positions in FHTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 313,925 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 109,394 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 109,394 |
| Jun 24, 26 | Lynch Thomas J. Jr. | other | 28,000 |
| Jun 24, 26 | Duty Stuart | other | 28,000 |
| Jun 24, 26 | Biller Scott | other | 28,000 |
| Jun 24, 26 | Gallagher Neil | other | 28,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FHTX coverage
Recent articles, reports, and earnings notes.
No research on FHTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FHTX report →Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
benzinga.com · Oct 1
Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart
barrons.com · Oct 1
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
globenewswire.com · Oct 1
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet
zacks.com · Aug 26
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy
zacks.com · Aug 14
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade
zacks.com · Aug 10
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates
zacks.com · Aug 6
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
globenewswire.com · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.